×
About 2,585 results

ALLMedicine™ Thymoma Center

Research & Reviews  952 results

Positron emission tomography/computed tomography differentiates resectable thymoma from...
https://doi.org/10.1016/j.jtcvs.2022.02.055
The Journal of Thoracic and Cardiovascular Surgery; Byrd CT, Trope WL et. al.

May 15th, 2022 - Discrete anterior mediastinal masses most often represent thymoma or lymphoma. Lymphoma treatment is nonsurgical and requires biopsy. Noninvasive thymoma is ideally resected without biopsy, which may potentiate pleural metastases. This study sough...

Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097348
Journal of Cardiothoracic Surgery; Zhou RQ, Li LJ et. al.

May 14th, 2022 - Post-thymectomy myasthenia gravis (PTMG) is defined as thymoma patients without signs of myasthenia gravis (MG) pre-operation, but develop MG after radical surgical resection. PTMG might be misdiagnosed not only because of its rare incidence, but ...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

May 13th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

A 47-Year-Old Japanese Woman with Symptoms of Increased Salty and Reduced Sweet Taste P...
https://doi.org/10.12659/AJCR.936000
The American Journal of Case Reports; Kimura M, Nakagawa H et. al.

May 3rd, 2022 - BACKGROUND Myasthenia gravis (MG) is an autoimmune neuromuscular disorder, which is often accompanied by various complications. Partial dysgeusia is an uncommon nonmotor symptom of MG, and dysgeusia preceding typical MG symptoms is rare. Although ...

see more →

Clinicaltrials.gov  44 results

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

May 13th, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

May 13th, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
https://clinicaltrials.gov/ct2/show/NCT02220855

Apr 11th, 2022 - Thymic tumors are rare tumors, but represent the most common tumors of the anterior mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to spread to the pleura. In first line therapy, combination chemotherapy pro...

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
https://clinicaltrials.gov/ct2/show/NCT01025089

Mar 8th, 2022 - The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thym...

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT01989598

Mar 2nd, 2022 - PRIMARY OBJECTIVES: I. To evaluate the antitumor activity of trametinib determined by overall response rate (ORR) in patients that are stratified into groups based on: biomarker positive (neuroblastoma RAS viral [v-ras] oncogene homolog [NRAS], v-...

see more →

News  35 results

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors
https://www.onclive.com/view/tas-117-shows-limited-efficacy-in-ovarian-breast-tumors

Apr 11th, 2021 - Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog (Akt) inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in thos...

Checkpoint Inhibitors in Small-Cell Lung Cancer
https://www.onclive.com/view/checkpoint-inhibitors-in-small-cell-lung-cancer

Apr 2nd, 2021 - Transcript: Mark A. Socinski, MD: One of the data sets that I thought was most encouraging at ASCO 2015 was the immunotherapeutic data for relapsed small-cell lung cancer where there’s a huge abyss of options. Roy, what were your thoughts about...

Eltrombopag Improves Response Rates in Severe Aplastic Anemia
https://www.onclive.com/view/eltrombopag-improves-response-rates-in-severe-aplastic-anemia

Dec 20th, 2020 - Danielle M. Townsley, MD More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive thera...

TERAVOLT Data Reveal "Unexpectedly High" Mortality in Patients With Thoracic Cancers and COVID-19
https://www.onclive.com/view/teravolt-data-reveal-unexpectedly-high-mortality-in-patients-with-thoracic-cancers-and-covid19

Dec 20th, 2020 - Marina Chiara Garassino, MD Early data from TERAVOLT, a global registry collecting characteristics and outcomes of patients with thoracic cancers affected by COVID-19, suggested an unexpectedly high mortality among this patient population, Marina...

Dr. Riess Discusses PD-L1 Expression in Thymic Malignancies
https://www.onclive.com/view/dr-riess-discusses-pd-l1-expression-in-thymic-malignancies

Dec 20th, 2020 - Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray. As PD-1 and PD-L1 antibodies have demonstrated benefit in other tum...

see more →

Patient Education  3 results see all →